Global Dihydropyridine Calcium Channel Blocker Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Dihydropyridine Calcium Channel Blocker Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Dihydropyridine (DHP) calcium channel blockers are derived from the molecule dihydropyridine and often used to reduce systemic vascular resistance and arterial pressure. Sometimes when they are used to treat angina, the vasodilation and hypotension can lead to reflex tachycardia, which can be detrimental for patients with ischemicsymptoms because of the resulting increase in myocardial oxygen demand. Dihydropyridine calcium channel blockers can worsen proteinuria in patients with nephropathy.
Dihydropyridine Calcium Channel Blocker report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Dihydropyridine Calcium Channel Blocker market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hypertension and Coronary Artery Disease are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Dihydropyridine Calcium Channel Blocker industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Dihydropyridine Calcium Channel Blocker key manufacturers include Pfizer, AstraZeneca, Abbott, Novartis, Sanofi, Sine Promod, Desano, Kang Lisheng Pharma and Guo Guang Pharma, etc. Pfizer, AstraZeneca, Abbott are top 3 players and held % sales share in total in 2022.
Dihydropyridine Calcium Channel Blocker can be divided into Norvasc, Plendil, DynaCirc and Cardene, etc. Norvasc is the mainstream product in the market, accounting for % sales share globally in 2022.
Dihydropyridine Calcium Channel Blocker is widely used in various fields, such as Hypertension, Coronary Artery Disease, Arrhythmia and Cardiomyopathy, etc. Hypertension provides greatest supports to the Dihydropyridine Calcium Channel Blocker industry development. In 2022, global % sales of Dihydropyridine Calcium Channel Blocker went into Hypertension filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Dihydropyridine Calcium Channel Blocker market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Pfizer
AstraZeneca
Abbott
Novartis
Sanofi
Sine Promod
Desano
Kang Lisheng Pharma
Guo Guang Pharma
Baiyunshan Pharma
Dawnrays
Segment by Type
Norvasc
Plendil
DynaCirc
Cardene
Others
Hypertension
Coronary Artery Disease
Arrhythmia
Cardiomyopathy
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Dihydropyridine Calcium Channel Blocker market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Dihydropyridine Calcium Channel Blocker, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Dihydropyridine Calcium Channel Blocker industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Dihydropyridine Calcium Channel Blocker in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Dihydropyridine Calcium Channel Blocker introduction, etc. Dihydropyridine Calcium Channel Blocker Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Dihydropyridine Calcium Channel Blocker market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Dihydropyridine Calcium Channel Blocker report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Dihydropyridine Calcium Channel Blocker market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hypertension and Coronary Artery Disease are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Dihydropyridine Calcium Channel Blocker industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Dihydropyridine Calcium Channel Blocker key manufacturers include Pfizer, AstraZeneca, Abbott, Novartis, Sanofi, Sine Promod, Desano, Kang Lisheng Pharma and Guo Guang Pharma, etc. Pfizer, AstraZeneca, Abbott are top 3 players and held % sales share in total in 2022.
Dihydropyridine Calcium Channel Blocker can be divided into Norvasc, Plendil, DynaCirc and Cardene, etc. Norvasc is the mainstream product in the market, accounting for % sales share globally in 2022.
Dihydropyridine Calcium Channel Blocker is widely used in various fields, such as Hypertension, Coronary Artery Disease, Arrhythmia and Cardiomyopathy, etc. Hypertension provides greatest supports to the Dihydropyridine Calcium Channel Blocker industry development. In 2022, global % sales of Dihydropyridine Calcium Channel Blocker went into Hypertension filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Dihydropyridine Calcium Channel Blocker market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Pfizer
AstraZeneca
Abbott
Novartis
Sanofi
Sine Promod
Desano
Kang Lisheng Pharma
Guo Guang Pharma
Baiyunshan Pharma
Dawnrays
Segment by Type
Norvasc
Plendil
DynaCirc
Cardene
Others
Segment by Application
Hypertension
Coronary Artery Disease
Arrhythmia
Cardiomyopathy
Others
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Dihydropyridine Calcium Channel Blocker market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Dihydropyridine Calcium Channel Blocker, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Dihydropyridine Calcium Channel Blocker industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Dihydropyridine Calcium Channel Blocker in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Dihydropyridine Calcium Channel Blocker introduction, etc. Dihydropyridine Calcium Channel Blocker Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Dihydropyridine Calcium Channel Blocker market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices